Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals
Συγγραφέας
Karanikas, V.; Soukou, F.; Kalala, F.; Kerenidi, T.; Grammoustianou, E. S.; Gourgoulianis, K. I.; Germenis, A. E.Ημερομηνία
2008Λέξη-κλειδί
Επιτομή
Survivin and its variant survivin-2B have been considered as potential candidates for cancer immunotherapy. The magnitude however of spontaneously occurring CD8+ T cells circulating precursor CTLs (pCTL), has never been evaluated. We set out to measure in 20 patients with lung carcinomas and 5 aged matched healthy male individuals (expressing HLA-A2 and/or -A24), the frequency of pCTLs specific for two naturally processed and presented peptides of survivin (LTLGEFLKL presented by HLA-A2) and survivin-2B (AYACNTSTL presented by HLA-A24) since these peptides are the only ones used in immunotherapeutic trials. The frequency of peptide-specific pCTLs was estimated using a sensitive method that combines HLA-multimer flow cytometric technology with a previous step of in vitro amplification under limiting dilution conditions. Anti-survivin or anti-survivin-2B specific CTL clones were not detected in 17 out of the 21 tested patients, and in none of the healthy individuals. In a number of peripheral blood mononuclear cell microcultures of the remaining 4 patients, diffuse clusters stained weakly by the HLA-multimers were observed which were not amplified after further stimulation and, therefore, they were finally considered as negative. The significance of the levels of spontaneously occurring CTL-responses against survivin and survivin-2B peptides, in cancer patients and cancer-free subjects, remains to be elucidated and it would be interesting to be considered in relation to the clinical efficacy of anti-cancer vaccination protocols. © 2008 Elsevier Inc. All rights reserved.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Low-frequency cd8+T cell precursors specific for survivin and survivin-2b in cancer patients: A caveat for immunotherapy?
Karanikas, V.; Soukou, F.; Kalala, F.; Kerenidi, T.; Gourgoulianis, K.; Germenis, A. (2008) -
Survivin regulation by HER2 through NF-kappa B and c-myc in irradiated breast cancer cells
Papanikolaou, V.; Iliopoulos, D.; Dimou, I.; Dubos, S.; Kappas, C.; Kitsiou-Tzeli, S.; Tsezou, A. (2011)Radiotherapy is an important treatment modality against cancer resulting in apoptosis and inhibition of cell growth. Survivin is an important cancer biomarker conferring to tumour cells increased survival potential by ... -
Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses
Speletas, M.; Argentou, N.; Karanikas, V.; Gramoustianou, E. S.; Mandala, E.; Braimi, M.; Matsouka, P.; Ritis, K.; Germenis, A. E. (2011)Tyrosine-kinase inhibitors are very effective in patients with CML, but in most cases the disease relapses after their discontinuation. As a result, novel approaches should be considered, such as anti-survivin treatment ...